Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AstraZeneca's ADC disappoints - on severe adverse events

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 06, 2024 6:09pm

130 Views

Post# 35919246

RE:RE:RE:RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

Upon Pelareorep's Accelerated Approval for HER2- negative Breast Cancer in 2024, market exclusivity would extend until 2037. And with market research projections indicating that the overall breast cancer market will be valued at US$73.68 billion by 2032, with a compound annual growth rate (CAGR) of 9.9%, the market is projected to grow to approximately US$118.56 billion by 2037.

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities